A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Wassim Abida

Memorial Sloan Kettering Cancer Center, New York, NY

Wassim Abida , Thomas Paul Bradley , Arash Rezazadeh , Lawrence Ivan Karsh , Ashley Ross , Daniel Saltzstein , Evren Kocabas Argon , Anthony Hamlett , Jeanie Tang , Deyaa Adib

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Mariona Calvo

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Mary-Ellen Taplin

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

First Author: Neeraj Agarwal

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).

First Author: Mary-Ellen Taplin